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Comparison of Nedaplatin and Irinotecan for Patients with
Squamous and Nonsquamous Cell Carcinoma of the Lung
Meta-Analysis of Four Trials
Fumihiro Oshita, MD, Takeshi Honda, MD, Shuji Murakami, MD, Tetsuro Kondo, MD,
Haruhiro Saito, MD, Kazumasa Noda, MD, and Kouzo Yamada, MD
Background: Non-small cell lung cancer has several types of
pathology and is moderately responsive to anticancer drugs, but
specific chemotherapy regimens for each have not been established.
Methods: We compared the outcomes of patients with squamous
and nonsquamous cell carcinoma of the lung, which were compiled
from four of our own studies of nedaplatin (NP) with irinotecan
(CPT).
Results: One hundred twenty-one patients with stage IIIB/IV
non-small cell lung cancer received 50 to 100 mg/m2 NP and 50
to 60 mg/m2 CPT per cycle. Eighty-six patients were men and 35
were women, with a median age of 70 years (range, 29–84
years). Seventeen, 88, 8, and 8 patients had a performance status
of 0, 1, 2, and 3, respectively. Twenty seven of the 121 patients
had squamous cell carcinoma. Responses to the NP and CPT
regimen were complete in two cases and partial in 45. The
response rate was 51.9 and 35.1% in patients with squamous and
nonsquamous cell carcinoma, respectively. Comparisons of sur-
vival revealed that the median survival time, 1-year survival rate,
and 2-year survival rate were 14.5 and 9.1 months, 63.0 and
39.4%, and 29.6 and 19.1% for patients with squamous and
nonsquamous cell carcinoma, respectively.
Conclusions: The NP and CPT regimen is suggested to be more
active against squamous cell carcinoma of the lung, and a compar-
ative study to confirm this is recommended.
Key Words: Nedaplatin, Irinotecan, Squamous cell carcinoma,
Lung cancer.
(J Thorac Oncol. 2011;6: 128–131)
Non-small cell lung cancer (NSCLC) has several types ofpathology, including adenocarcinoma, squamous cell
carcinoma, large cell carcinoma, and others. All types of
NSCLC are moderately responsive to anticancer drugs, and
specific chemotherapy regimens for each have not been
established. Regimens based on combinations of new anti-
cancer agents such as vinorelbine, gemcitabine, docetaxel,
and paclitaxel with platinum compounds have emerged as a
gold standard for chemotherapy-naive NSCLC.1 The epider-
mal growth factor receptor (EGFR) tyrosine kinase inhibitor
gefitinib has been shown to have high efficacy in patients
with previously treated advanced NSCLC.2 Specific missense
and deletion mutations in the tyrosine kinase domain of the
EGFR gene are reportedly associated with sensitivity to
gefitinib,3,4 and patients with NSCLC with EGFR mutation
have been retrospectively demonstrated to achieve a better
outcome with gefitinib treatment than the patients with the
wild-type EGFR.5 We have also found that patients with
EGFR mutation have a significantly higher response rate to
gefitinib, and also significantly longer survival, than patients
with wild-type EGFR.6 Currently, therefore, NSCLC with
EGFR mutation is an independent pathologic type that is
considered to require a specific chemotherapy regimen.
Pemetrexed is a potent inhibitor of thymidylate syn-
thase and other folate-dependent enzymes and is currently
approved as a first-line treatment for malignant pleural me-
sothelioma. A randomized phase III study has shown that a
regimen comprising cisplatin and pemetrexed provides sim-
ilar efficacy with better tolerability and more convenient
administration than cisplatin and gemcitabine as a first-line
treatment for advanced NSCLC.7 The study also demon-
strated that cisplatin and pemetrexed provided better overall
survival in patients with adenocarcinoma and large cell car-
cinoma. Therefore, these recent studies suggest that uniform
treatment for NSCLC may not be appropriate, and that
treatment needs to be tailored according to histologic or
genetic type.
Nedaplatin (NP) is an analogue of cisplatin, with rela-
tively low neuro- and nephrotoxicity. Three-dimensional an-
alytical models have demonstrated marked synergistic inter-
action of concurrently administered NP and irinotecan
(CPT).8 A phase I/II study showed high activity and low
toxicity of NP and CPT against NSCLC,9 and some other
studies of NP and CPT against advanced NSCLC yielded
similar results, together with favorable patient survival.10–12
No differences in activity among histologic types were evi-
dent, but NP was basically active against squamous cell
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carcinoma. Here, we analyze the outcomes of our previously
published studies using NP and CPT for chemotherapy-naive
patients with NSCLC and compare them between squamous
and nonsquamous cell carcinoma.
PATIENTS AND METHODS
We analyzed four studies, (1) phase I/II study of esca-
lating doses of NP in combination with CPT for advanced
NSCLC,9 (2) phase II study of NP and CPT for elderly
patients with advanced NSCLC,10 (3) feasible combination of
chemotherapy with NP and CPT for patients with NSCLC
and multiple high-risk factors,11 (4) phase II study of NP and
CPT followed by gefitinib for elderly patients with unresect-
able NSCLC.12 The Institutional Review Board of Kanagawa
Cancer Center reviewed and approved every study analyzed
in this investigation.
Patients
Patients with histologically or cytologically proven
unresectable NSCLC were registered for each study of NP
and CPT. Eligibility criteria for the chemotherapy were
absence of any prior chemotherapy and Eastern Cooperative
Oncology Group performance status score 3. Patients with
postoperative recurrence and patients who had received ra-
diotherapy for metastatic lesions were eligible for each study,
and at least 4 weeks rest was required after prior surgery or
radiation therapy. Written informed consent was obtained in
every case.
Chemotherapy
Patients exhibiting no progression of the disease were
treated every 4 weeks with CPT on days 1 and 8, and with NP
on day 1 only or on days 1 and 8. CPT was used at 50 or 60
mg/m2 on each day, and NP was used at 50 to 100 mg/m2 on
each day (Table 1). The NP and CPT chemotherapy was
repeated for a maximum of four cycles unless the disease
progressed or if severe toxicities developed. Tumor responses
were evaluated according to the RECIST criteria.13
Statistical Analysis
The 2 test was used to identify differences between
squamous and nonsquamous cell carcinoma. The Kaplan-
Meier method was used to estimate the probability of sur-
vival, and differences in survival were analyzed by the
log-rank test. All analyses were performed using StatView or
Fisher’s software.
RESULTS
Between April 1997 and January 2006, a total of 139
patients were registered in the four studies. One hundred
twenty one of them had clinical stage IIIB or IV disease, and
their outcomes were analyzed in this study. Eighty-six pa-
tients were men and 35 were women, with a median age of 70
years (range, 29–84 years). Seventeen, 88, 8, and 8 patients
had a performance status of 0, 1, 2, and 3, respectively.
Twenty-seven patients had squamous cell carcinoma. Twen-
ty-five and 96 patients were at stages IIIB and IV, respec-
tively. Patient characteristics in each group are summarized
in Table 2. All patients were assessed for response and
survival. Responses to the NP and CPT regimen in the 121
patients were complete in two cases and partial in 45. Both of
the patients who achieved a complete response and whose
tumors did not recur for 5 years had squamous cell carci-
noma. The response rate was 51.9 and 35.1% for patients
with squamous and nonsquamous cell carcinoma, respec-
tively. Comparison of survivals among the various pathologic
types revealed that the median survival time, 1-year survival
rate, and 2-year survival rate were 14.5 and 9.1 months, 63.0
and 39.4%, and 29.6 and 19.1% for squamous and nonsqua-
mous cell carcinoma, respectively (Table 3).
DISCUSSION
NP has been shown to have antitumor activity against
squamous cell carcinoma originating from multiple organs
such as the lung,14 esophagus,15 head and neck,16 and uterine
cervix.17 Not only CPT but also other drugs such as do-
cetaxel, paclitaxel, and 5-fluorouracil have been combined
with NP and demonstrated to have activity against squamous
cell carcinoma of these organs.14–17 Although we were unable
to find any differences in treatment outcome between squa-
mous and nonsquamous cell carcinoma in each of the previ-
ous studies, the present meta-analysis suggested that NP and
CPT elicit favorable responses and survival in patients with
squamous cell carcinoma. A randomized phase III study that
demonstrated a significant improvement in survival with cispla-
tin plus pemetrexed in patients with adenocarcinoma suggested
that higher baseline expression of the thymidylate synthase gene
and protein was related to the difference in survival.7 It has been
suggested that NP is more effective against squamous cell
carcinoma than against adenocarcinoma,18 although the
mechanism of sensitivity to NP in lung cancer has not been
elucidated. For squamous cell carcinoma, predictors of tumor
TABLE 1. Summary of Studies
Phase n NP (mg/m2/d)
CPT
(mg/m2/d)
Clinical
Stage
Age (yr),
Median
(Range)
Gr. 3/4
Diarrea
(%)
Gr. 4
Neut. (%)
FN
(%)
RR
(%) MST (mo)
1-yr Surv
(%) Reference
I/II 42 50–100 (day 1) 60 (days 1, 8) IIIA-IV 55 (29–69) 1.0 9.3 12.4 31.0 11.4 45.2 9
II 38 100 (day 1) 60 (days 1, 8) IIB-IV 74 (71–84) 7.9 50.0 26.3 65.8 13.9 55.3 10
II 28 50 (days 1, 8) 60 (days 1, 8) IIIB/IV 74 (70–81) 1.4 33.8 4.2 39.3 8.7 42.9 12
Pilot 31 50 (days 1, 8) 50 (days 1, 8) IB-IV 63 (30–86) 0 8.4 13.3 45.2 7.7 (IIIB/IV) 38.5 (IIIB/IV) 11
We deleted 18 patients with stage IB to IIIA and analyzed patients with stage IIIB or IV.
NP, nedaplatin; CPT, irinotacan; gr., grade; neut., neutropenia; FN, febrile neutropenia; RR, response rate; MST, median survival rate; 1-yr surv, 1-yr survival rate.
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response to chemotherapy have been investigated in other
organs, from which samples of tumor tissue can be easily
obtained for analysis of genetic expression. Expression of
Her-2 and EGFR in tumor tissue has been shown to be a
potentially reliable predictive indicator of sensitivity to cis-
platin in head and neck squamous cell cancer.19 Another
study has revealed that tumors with p53 mutation are more
common among nonresponders to neoadjuvant chemotherapy
in patients with head and neck squamous cell carcinoma.20
Repair-related genes, such as ERCC-1 or XRCC1, are known
to be good predictors of chemotherapeutic response in esoph-
ageal squamous cell carcinoma.21,22 Chemosensitivity of
squamous cell carcinoma of the lung had not been analyzed
because of the low availability of tumor tissues for gene
analysis in patients with unresected advanced NSCLC. We
have suggested that DNA damage in peripheral blood mono-
nuclear cells can be predictive of response to cisplatin-
based chemotherapy.23 It suggest that DNA from periph-
eral blood cells or cancer tissue may be available for
analysis of genetic predictors of chemosensitivity, and we
anticipate the emergence of a reliable biomarker for pre-
diction of sensitivity to NP.
CONCLUSIONS
NP and CPT is suggested to be more effective against
squamous cell carcinoma than against nonsquamous cell
carcinoma, and a large comparative study to confirm this
seems warranted.
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